The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, VideosJuly 20, 2020
EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosisAL amyloidosisJune 14, 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?AL amyloidosis, MPE, MyelomaMay 8, 2020
MPE webinar on personalised medicines in myeloma and AL amyloidosisAL amyloidosis, MPE, MyelomaApril 28, 2020
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19MyelomaApril 14, 2020
MPE webinar on Minimal Residual Disease (MRD) in myeloma and related diseasesMPE, MyelomaApril 13, 2020
